SCHEMBL4473424

SCHEMBL4473424

CNC(=O)c1cc(Oc2cccc(-c3c[nH]c(C(=O)Nc4ccc(C(C)(C)C)cc4)c3)c2)ccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 7/20 0.54
RAF1 P04049 9/20 0.53
BRAF P15056 9/20 0.53
RET P07949 2/20 0.51
LCK P06239 2/20 0.51
FYN P06241 2/20 0.51
HIPK4 Q8NE63 2/20 0.51
PLK4 O00444 1/20 0.51
AURKA O14965 1/20 0.51
MAPK13 O15264 1/20 0.51
JAK2 O60674 1/20 0.51
MAP4K4 O95819 1/20 0.51
ABL1 P00519 1/20 0.51
LYN P07948 1/20 0.51
ROS1 P08922 1/20 0.51
SRC P12931 1/20 0.51
RPS6KB1 P23443 1/20 0.51
EPHA2 P29317 1/20 0.51
TYK2 P29597 1/20 0.51
AXL P30530 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4466760 0.87 KDR (0.70) KDRRAF1BRAFRETLCK
SCHEMBL9106204 0.87 KDR (0.65) KDRRAF1BRAFRETLCK
SCHEMBL9099762 0.87 KDR (0.42) KDRRAF1BRAFRETLCK
SCHEMBL4463621 0.87 RET (0.55) KDRRAF1BRAFRETLCK
SCHEMBL4469341 0.85 BRAF (0.56) KDRRAF1BRAFRETLCK
SCHEMBL4467857 0.85 RET (0.51) KDRRAF1BRAFRETLCK
SCHEMBL4466558 0.84 RET (0.71) KDRRAF1BRAFRETLCK
SCHEMBL4466716 0.84 RAF1 (0.65) KDRRAF1BRAFRETLCK
SCHEMBL4485725 0.84 RET (0.50) KDRRAF1BRAFRETLCK
SCHEMBL4480048 0.82 RET (0.55) KDRRAF1BRAFRETLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1685125-B1 Pyrrole derivatives useful for the treatment of proliferative diseases MERCK PATENT GMBH (DE) 2012-06-06 EP claimed
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US claimed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US claimed
US-7598274-B2 N-methyl-4-{4-[5-(4-chloro-3-trifluoromethylphenylcarbamoyl)-1H-pyrrol-3-yl]-phenoxy}pyridine-2-carboxamide; Raf kinases inhibitors MERCK PATENT GMBH (DE) 2009-10-06 US disclosed
US-20070149594-A1 Pyrrole derivatives MERCK PATENT GMBH (DE) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149594-A1 Pyrrole derivatives RAF1, BRAF, ARAF KDR 2076/4885RAF1 1/4885BRAF 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.